Related references
Note: Only part of the references are listed.Dose Escalation in Stereotactic Body Radiation Therapy for Pancreatic Cancer A Meta-Analysis
Nicholas G. Zaorsky et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
EUS-guided fiducial placement for GI malignancies: a systematic review and meta-analysis
Emmanuel Coronel et al.
GASTROINTESTINAL ENDOSCOPY (2019)
Investigating Potential Bias in Patient-Reported Outcomes in Open-label Cancer Trials
Jessica K. Roydhouse et al.
JAMA ONCOLOGY (2019)
The challenges and opportunities of using patient reported outcome measures (PROMs) in clinical practice
Michael Fleischmann et al.
INTERNATIONAL JOURNAL OF OSTEOPATHIC MEDICINE (2018)
Dose escalation for locally advanced pancreatic cancer: How high can we go?
Lauren E. Colbert et al.
ADVANCES IN RADIATION ONCOLOGY (2018)
Pancreatic Adenocarcinoma, Version 2.2017
Margaret A. Tempero et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Integration of Stereotactic Body Radiation Therapy into the Multidisciplinary Management of Pancreatic Cancer
Lauren M. Rosati et al.
SEMINARS IN RADIATION ONCOLOGY (2017)
Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC
Lauren E. Colbert et al.
ADVANCES IN RADIATION ONCOLOGY (2017)
Use and misuse of common terminology criteria for adverse events in cancer clinical trials
Sheng Zhang et al.
BMC CANCER (2016)
The use of and adherence to CTCAE v3.0 in cancer clinical trial publications
Sheng Zhang et al.
ONCOTARGET (2016)
The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience
Shalini Moningi et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Phase 2 Multi-institutional Trial Evaluating Gemcitabine and Stereotactic Body Radiotherapy for Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma
Joseph M. Herman et al.
CANCER (2015)
Stereotactic body radiation therapy in pancreatic cancer: the new frontier
Shalini Moningi et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2014)
The use of fiducial markers in image-guided radiotherapy for gastric cancer
Joseph Sia et al.
JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY (2013)
A DOSIMETRIC MODEL OF DUODENAL TOXICITY AFTER STEREOTACTIC BODY RADIOTHERAPY FOR PANCREATIC CANCER
James D. Murphy et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2010)
DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer
Christine A. Iacobuzio-Donahue et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Is there room for improvement in adverse event reporting in the era of targeted therapies?
Maureen Edgerly et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Prospects and challenges in using patient-reported outcomes in clinical practice
Constance H. Fung et al.
QUALITY OF LIFE RESEARCH (2008)
Stereotactic body radiation therapy (SBRT) for lung metastases
Paul Okunieff et al.
ACTA ONCOLOGICA (2006)
Dose-finding based on efficacy-toxicity trade-offs
PF Thall et al.
BIOMETRICS (2004)
Share Paper
